Our findings demonstrated that two novel, highly selective STAT3 allosteric inhibitors, HCB-5300 and HCB-5400, show significant anti-inflammatory effects in a DSS-induced murine model of acute colitis, suggesting their potential as a therapeutic strategy for managing acute inflammatory episodes in IBD, particularly UC. This evidence concerns the gene STAT3 and inflammatory bowel disease.